danicopan
Selected indexed studies
- Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. (Lancet Haematol, 2023) [PMID:38030318]
- Danicopan: First Approval. (Drugs, 2024) [PMID:38528310]
- Danicopan. (, 2006) [PMID:39836823]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. (2023) pubmed
- Danicopan: First Approval. (2024) pubmed
- Danicopan. (2006) pubmed
- Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH. (2025) pubmed
- Danicopan. (2024) pubmed
- Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis. (2024) pubmed
- Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria. (2024) pubmed
- PMID:39808035 (2024) pubmed
- PMID:40294197 (2025) pubmed
- PMID:39693457 (2024) pubmed